Polio

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

Global Reverse Osmosis Systems Market (2021 to 2026) - Featuring Alfa Laval, Applied Membranes and Dupont Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 10, 2022 - 4:31pm

Moreover, the rise in urban population and disposable income is also expected to fuel the market growth.

Key Points: 
  • Moreover, the rise in urban population and disposable income is also expected to fuel the market growth.
  • The rising investment, worldwide, to develop novel and advanced water treatment infrastructure is also expected to fuel the market growth.
  • Global estimates have been ranging from US$6.7 trillion, by the year 2030, to around US$22.6 trillion by the year 2050.
  • Countries, such as India and China, are expected to register significant market growth in the coming years.

PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm

Retrieved on: 
Tuesday, January 4, 2022 - 2:15pm

PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.
  • The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries.
  • Under the terms of this agreement, Zydus will transfer its manufacturing technology and provide technical assistance to Enzychem Lifesciences.
  • The vaccine is administered intradermally using the PharmaJet needle-free system, which can be deployed more readily, especially in resource-poor populations where these are urgently needed.

GLIDE: Yemeni Doctor Wins Global Disease Elimination Award to Help Keep the Country Free of Lymphatic Filariasis

Retrieved on: 
Monday, December 13, 2021 - 5:00am

Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.

Key Points: 
  • Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.
  • The five winners were announced yesterday by the Global Institute for Disease Elimination (GLIDE) during a Universal Health Coverage Day event at EXPO 2020 Dubai.
  • Dr Al-Kubati beat 220 applicants across 44 countries to become the first Yemeni winner of the Falcon Awards.
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

GLIDE: Vaccination Incentives and Next Generation Sequencing – Two Pakistani Doctors Employ Innovative Techniques to Eradicate Polio

Retrieved on: 
Monday, December 13, 2021 - 3:00am

Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.

Key Points: 
  • Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.
  • It is possible his methods could also be used to control other infectious diseases in the region, including COVID-19.
  • With GLIDEs support, my project will focus on improving polio vaccination coverage in these high-risk areas which will hopefully contribute to eradicating this disease from the world.
  • Dr Das and Dr Salman beat 220 applicants across 44 countries to become the first Pakistani winners of the Falcon Awards.

GLIDE: End of Malaria and Lymphatic Filariasis in Sight for Philippines, Says Award-winning Filipino Doctor

Retrieved on: 
Monday, December 13, 2021 - 12:00am

Great achievements have been made in the Philippines to tackle malaria and LF to date.

Key Points: 
  • Great achievements have been made in the Philippines to tackle malaria and LF to date.
  • However, elimination of these diseases remains problematic, and over the last five years, the country has struggled to reduce their prevalence.
  • Dr Espino beat 220 applicants across 44 countries to become the first Filipino winner of the Falcon Awards.
  • Great achievements have been made towards the 2030 goal of the elimination of malaria and lymphatic filariasis.

The Global Institute for Disease Elimination awards USD1 million to ground-breaking health projects in endemic countries

Retrieved on: 
Sunday, December 12, 2021 - 1:00pm

The Global Institute for Disease Elimination (GLIDE) has announced the winners of its inaugural Falcon Awards for Disease Elimination.

Key Points: 
  • The Global Institute for Disease Elimination (GLIDE) has announced the winners of its inaugural Falcon Awards for Disease Elimination.
  • The Falcon Awards will support community-based initiatives by empowering local actors with the tools and financial backing to rid the world of these preventable diseases.
  • For more information on The Falcon Awards for Disease Elimination and the winners, please visit: https://glideae.org/awards
    For photos of the winners, please click here .
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

InDevR Launches ArrayMax Mixer for Even Faster VaxArray Assay Times

Retrieved on: 
Tuesday, November 16, 2021 - 8:00am

BOULDER, Colo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its new ArrayMaxTM Mixer to provide significantly reduced assay times for its VaxArray Portfolio of immunoassay kits.

Key Points: 
  • BOULDER, Colo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its new ArrayMaxTM Mixer to provide significantly reduced assay times for its VaxArray Portfolio of immunoassay kits.
  • Current VaxArray Assays include kits for influenza, coronavirus, measles/rubella, and polio, and provide vaccine manufacturers faster characterization of identity, quantity, and stability parameters during manufacture and release of vaccine products.The ArrayMax Mixer significantly improves mixing over static incubation or traditional orbital shakers during assay execution using either antibody or antigen samples.In internal validation studies comparing ArrayMax to original VaxArray protocols, similar or improved analytical performance was obtained using new ArrayMax-executed VaxArray protocols and up to an 85% reduction of time to result was obtained.
  • In a small 6"x 6" footprint, this convenient new tool provides the possibility to generate VaxArray results in a fraction of the time compared to traditional ELISA, providing a total assay time of less than onehour for currently available VaxArray Kits.
  • Erica Dawson, CTO of InDevR, noted, "Our VaxArray Assay Kits already provide significant advantages over outdated, laborious, and error prone techniques such as SRID, TCID50, and ELISAs.This further reduction in total assay time for the VaxArray Kits will benefit any vaccine development or manufacturer in bioprocess development, optimization and monitoring, as well as vaccine release testing.We are excited to continue empowering vaccine producers by further expanding our portfolio."

PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress

Retrieved on: 
Monday, November 15, 2021 - 2:10pm

PharmaJet , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17.
  • The presentation, entitled Improving Vaccine Performance with Needle-free Delivery, is being presented by Paul LaBarre, MS, MBA, Vice President, Global Business Development.
  • The vaccine will be delivered exclusively with the PharmaJet Tropis Intradermal Needle-free Injection System.
  • PharmaJets mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.

March Of Dimes 2021 Report Card Examines State Of Maternal And Infant Health In Louisiana

Retrieved on: 
Monday, November 15, 2021 - 2:31pm

In Louisiana, the preterm birth rate fell from 13.1% to 12.9% in 2020, earning the state an F grade on this year's Report Card.

Key Points: 
  • In Louisiana, the preterm birth rate fell from 13.1% to 12.9% in 2020, earning the state an F grade on this year's Report Card.
  • The Report Card highlights the stark disparities that cut across all measures of maternal and infant health and outlines the policy actions and partnerships needed to improve the health of our nation's families.
  • A challenge as complex as thematernal and infant health crisisinShreveport, for example, requires the dedication and resources of cross-sector partners working together.
  • Before becoming leaders in maternal and infant health, March of Dimes was known for conquering the polio epidemic (Historical footage and photos available).